Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Andrew Stephenson, M.D., is the Director for the Center of Urologic Oncology at Cleveland Clinic's Glickman Urological and Kidney Institute and a staff member of the Taussig Cancer Institute. His clinical and research focus is the treatment of patients with cancers of prostate, bladder, testis, and kidney. He has published over 100 articles in peer-reviewed journals on issues related to prostate, bladder, kidney and testis cancer. Dr. Stephenson is board-certified in urology by the American Board of Urology and the Royal College of Physicians and Surgeons of Canada. He has received several awards from organizations such as the Prostate Cancer Foundation, American Society of Clinical Oncology, and Society of Urologic Oncology. He is listed as one of the Best Doctors in America. He is a past recipient of the Urology Teacher of the Year award from Cleveland Clinic and the Young Investigator Award from the Society of Urologic Oncology. He has also been recognized as a Rising Star in Urology by the American Urological Association. Dr. Stephenson receives grant support for prostate cancer research from the Robert Wood Johnson Foundation, American Cancer Society, and the Urology Care Foundation. His research focus is on improving decision-making for patients and physicians for complex urological cancers. He is on the editorial board for several urology and oncology journals. Dr. Stephenson has extensive experience in robotic and open surgical procedures for cancers of the prostate, bladder, and kidney. He performs nerve-sparing procedures for prostatectomy, cystectomy, and retroperitoneal lymph node dissection. For patients undergoing cystectomy, he has extensive experience in all forms of urinary diversion/reconstruction.
Prostate cancer, bladder cancer, testis cancer, kidney cancer, robotic prostatectomy, robotic cystectomy, urinary diversion
Awards & Honors
Best Doctors in America; Young Investigator Award, Society of Urologic Oncology; Rising Stars in Urology, American Urological Association Foundation; Urology Teacher of the Year, Cleveland Clinic
Innovations & Patents
Development of several nomograms for prostate cancer. These prognostic models provide accurate predictions of treatment outcome for prostate cancer and are widely used for the counseling of patients with localized and advanced prostate cancer.
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 12/10/2015, Dr. Stephenson has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.